Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases

Oncology Reports

Volumn 20, Issue 3, 2008, Pages 619-624

  Warnecke Eberz, Ute ^a   Bollschweiler, Elfriede ^a   Drebber, Uta ^a   Pohl, Alexandra ^a   Baldus, Stephan E ^b   Hoelscher, Arnulf H ^a   Metzger, Ralf ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Gene expression; Lung cancer; Lymph node metastases; Oncogene; Tumor progression

Indexed keywords

BETA ACTIN; MESSENGER RNA; PROTEIN KINASE PIM 1; PIM1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; EARLY CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; ENZYME IMMUNOASSAY; GENETICS; LUNG TUMOR; LYMPH NODE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-PIM-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 54549086528     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000050     Document Type: Article

References (35)

1. AC Society. Cancer Facts & Figures 2006. American Cancer Society, Atlanta, GA, 2006.
2. Jemal A, Murray T, Ward E, et al: Cancer statistics. CA Cancer J Clin 55: 10-30, 2005.
3. World Health Organization: The World Health Organization histologic typing of lung tumors. Am J Clin Pathol 77: 123-136, 1982.
4. Bulzebruck H, Bopp R, Drings P, et al: New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 70: 1102-1110, 1992.
5. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 18: 106-115, 2000.
6. Rosell R, Felip E, Garcia-Campelo R and Balana C: The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer 46: 135-148, 2004.
7. Herbst RS, Onn A and Sandler A: Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23: 3243-3256, 2005.
8. Meyerson M, Franklin WA and Kelley MJ: Molecular classification and molecular genetics of human lung cancers. Semin Oncol 31: 4-19, 2004.
9. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR and Albelda SM: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11: 3974-3986, 2005.
10. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J and Magnuson NS: Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593: 45-55, 2002.
11. Bachmann M, Hennemann H, Xing PX, Hoffmann I and Moroy T: The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of C-TAK1: a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 279: 48319-48328, 2004.
12. Bullock AN, Debreczeni J, Amos AL, Knapp S and Turk BE: Structure and substrate specificity of the pim-1 kinase. J Biol Chem 280: 41675-41682, 2005.
13. Bhattacharya N, Wang Z, Davitt C, McKenzie IF, Xing PX and Magnuson NS: Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 111: 80-95, 2002.
14. Saris CJM, Domen J and Berns A: The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 10: 655-664, 1991.
15. Xie Y, Xu K, Dai B, Guo Z, Jiang T, Chen H and Qiu Y: The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 25: 70-78, 2006.
16. Selten G, Cuypers HT and Berns A: Proviral activation of the putative oncogene Pim-1 in MulV induced T-cell lymphomas. EMBO J 4: 1793-1798, 1985.
17. Shay KP, Wang Z, Xing OX, McKenzie IF and Magnuson NS: Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res 3: 170-181, 2005.
18. Amaravadi R and Thompson CB: The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618-2624, 2005.
19. Dhanasekaran SM, Barrette TR, Ghosh D, et al: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001.
20. Chen CN, Lin JJ, Chen JJ, et al: Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol 23: 7286-7295, 2005.
21. Schneider PM, Praeuer HW, Stoeltzing O, et al: Multiple molecular marker testing (p53, c-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 83: 473-479, 2000.
22. Warnecke-Eberz U, Metzger R, Miyazono F, et al: High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for predicition of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 10: 3794-3799, 2004.
23. Warnecke-Eberz U, Hokita S, Xi H, et al: Overexpression of survivin mRNA is associated with a favourable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 13: 1241-1246, 2005. 24 LeBlanc M, Jacobson J and Crowley J: Partitioning and peeling for constructing prognostic groups. Stat Methods Med Res 11: 247-274, 2002.
24. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 187-220, 1958.
25. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Chemother Rep 50: 163-170, 1966.
26. Beier UH, Weise JB, Laudien M, Sauerwein H and Gorogh T: Overexpression of Pim-1 in head and neck squamous cell carcinomas. Int J Oncol 30: 1381-1387, 2007.
27. Valdman A, Fang X, Pang ST, Ekman P and Egevad L: Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60: 367-371, 2004.
28. Cibull TL, Jones TD, Li L, et al: Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol 59: 285-288, 2006.
29. Rahman Z, Yoshikawa H, Nakajima Y and Tasaka K: Down-regulation of Pim-1 and Bcl-2 is accompanied with apoptosis of interleukin-6-depleted mouse B-cell hybridoma 7TD1 cells. Immunol Lett 75: 199-208, 2001.
30. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R and Dalla-Favera R: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412: 341-346, 2001.
31. Mitelman F, Mertens F and Johansson B: A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15: 417-424, 1997.
32. Knuutila S, Aalto Y, Autio K, et al: DNA copy number losses in human neoplasms. Am J Pathol 155: 683-694, 1999.
33. Cuypers HT, Selten G, Quint W, et al: Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37: 141-150, 1984.
34. Van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T and Berns A: Predisposition to lymphoma-genesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukaemia virus-induced tumors. Cell 56: 673-682, 1989.
35. Schmidt T, Karsunky H, Gau E, Zevnik B, Elsasser HP and Moroy T: Zinc finger protein GFI-I has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis. Oncogene 117: 2661-2667, 1998.